Pulmonx reported a 5% year-over-year increase in revenue to $21.5 million in Q3 2025, driven by international growth. Gross margin improved slightly to 75%, though the company remained unprofitable with a net loss of $14.0 million and an adjusted EBITDA loss of $8.2 million.

Pulmonx achieved worldwide revenue of $23.9 million in Q2 2025, a 15% increase year-over-year, driven by strong international performance. Despite this growth, the company revised its full-year revenue guidance downwards due to slower-than-expected revenue conversion from U.S. initiatives, while also reducing its operating expense outlook.

Pulmonx reported a strong start to 2025 with worldwide revenue of $22.5 million, a 20% increase year-over-year, driven by continued commercial execution and global adoption of Zephyr Valve procedures. Despite the revenue growth, the company reported a net loss of $14.4 million.

Pulmonx reported record worldwide revenue of $23.8 million for Q4 2024, a 23% increase year-over-year, and $83.8 million for the full year 2024, a 22% increase. The company also achieved a gross margin of 74% for both the quarter and the full year, and reduced its net loss compared to the previous year.

Pulmonx Corporation reported a 15% increase in worldwide revenue to $20.4 million for the third quarter of 2024, with U.S. revenue up 17% to $13.8 million. The company maintained a gross margin of 74%.

Pulmonx reported record worldwide revenue of $20.8 million for Q2 2024, a 21% increase year-over-year. U.S. revenue grew by 26% to $13.9 million. The company maintained a gross margin of 74%.

Pulmonx reported first quarter 2024 financial results, achieving a 30% year-over-year worldwide revenue growth. The company's U.S. revenue increased by 38%, and it realized a gross margin of 75%.

Pulmonx Corporation reported a 25% increase in worldwide revenue for Q4 2023, reaching $19.3 million, with significant growth in the U.S. market. The company's gross margin improved to 75%, and it added 14 new Zephyr Valve U.S. treatment centers. They anticipate continued growth and expansion in 2024.

Pulmonx reported record third-quarter results with worldwide revenue of $17.7 million, a 31% increase year-over-year. U.S. revenue grew by 41% to $11.8 million. The company is increasing its full-year revenue expectation to $67 million to $68 million.

Pulmonx reported a 23% increase in worldwide revenue, reaching $17.2 million in Q2 2023. U.S. revenue grew by 28% to $11.0 million. The company is increasing its full-year revenue expectation to $64 million to $66 million.

Pulmonx reported a 35% increase in worldwide revenue to $14.5 million for the first quarter of 2023, with U.S. revenue increasing by 55%. The company's gross margin was 73%.

Pulmonx Corporation reported a 13% increase in worldwide revenue for the fourth quarter of 2022, reaching a record $15.4 million. U.S. revenue also hit a record of $9.5 million, a 30% increase year-over-year. The company's gross margin was 73% for the quarter.

Pulmonx Corporation reported a 2% increase in worldwide revenue for Q3 2022, driven by a 22% increase in U.S. revenue. Gross margin improved to 75%. However, operating expenses increased by 23%, resulting in a net loss of $14.2 million, compared to $10.2 million in the same period last year.

Pulmonx reported a strong second quarter with worldwide revenue reaching $14.0 million, a 14% increase year-over-year. The company also achieved a gross margin of 75% and added 18 new U.S. treatment centers for Zephyr Valves.

Pulmonx reported a 17% increase in worldwide revenue, reaching $10.8 million in Q1 2022, with a gross margin of 75%. The company added 16 new U.S. treatment centers, increasing the total to 230.

Pulmonx Corporation reported a 39% increase in worldwide revenue for the fourth quarter of 2021, reaching $13.7 million. The company's gross margin also improved to 74.8%. Despite COVID headwinds, the company expanded its base of U.S. treatment centers and submitted a regulatory filing seeking Zephyr Valve approval in Japan.

Pulmonx reported a 25% increase in worldwide revenue to $13.3 million for Q3 2021, with a gross margin of 73%. The company is maintaining its full year 2021 revenue guidance in the range of $49 to $51 million.

Pulmonx Corporation reported a significant increase in revenue for the second quarter of 2021, with worldwide revenue reaching $12.2 million, a 232% increase compared to the same period last year. The company's gross margin also improved significantly, reaching 74% compared to 28% in the second quarter of 2020. They are updating its full year 2021 revenue guidance to be in the range of $49 to $51 million.

Pulmonx Corporation reported a 7% increase in worldwide revenue for the first quarter of 2021, totaling $9.2 million. The company experienced a gross margin of 71.5%, an increase from 65.6% in the same period last year. While U.S. revenue decreased by 5%, international revenue rose by 20%.

Pulmonx Corporation reported a slight decline in worldwide revenue for Q4 2020, primarily due to the impact of the COVID-19 pandemic on international revenue. However, U.S. revenue saw an increase driven by expanded commercialization efforts. The company's gross profit and margin remained strong, but operating expenses increased due to investments in commercial and R&D functions.

Pulmonx reported a 17% increase in revenue compared to the same quarter last year, with a relatively flat gross margin. The company completed an initial public offering, raising approximately $201.4 million. They also secured a positive coverage decision for Zephyr Valve from Health Care Service Corporation, adding 16 million additional lives under coverage.